Clinical Takeaway
People with PTSD and co-occurring substance use disorders who use cannabis can still benefit meaningfully from trauma-focused treatments. Clinicians should not withhold or delay evidence-based PTSD care based on a patient’s cannabis use status.
#5 Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.
Citation: Hill Melanie L et al.. Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.. Journal of anxiety disorders. 2024. PMID: 38266511.
Design: 6 Journal: 0 N: 4 Recency: 1 Pop: 2 Human: 1 Risk: -2
This meta-analysis clarifies whether cannabis use compromises the effectiveness of trauma-focused cognitive behavioral therapy in patients with comorbid PTSD and substance use disorders, a population frequently excluded from clinical trials despite high prevalence rates. The findings directly address a critical clinical gap by providing evidence on treatment outcomes for a real-world patient population, informing whether cannabis use requires modified treatment protocols or patient stratification. These results have immediate implications for clinical decision-making regarding treatment selection and expected response rates in dual-diagnosis populations.
Quality Gate Alerts:
- Preclinical only
Abstract: High rates of cannabis use among people with posttraumatic stress disorder (PTSD) have raised questions about the efficacy of evidence-based PTSD treatments for individuals reporting cannabis use, particularly those with co-occurring alcohol or other substance use disorders (SUDs). Using a subset of four randomized clinical trials (RCTs) included in Project Harmony, an individual patient meta-analysis of 36 RCTs (total N = 4046) of treatments for co-occurring PTSD+SUD, we examined differences in trauma-focused (TF) and non-trauma-focused (non-TF) treatment outcomes for individuals who did and did not endorse baseline cannabis use (N = 410; 70% male; 33.2% endorsed cannabis use). Propensity score-weighted mixed effects modeling evaluated main and interactive effects of treatment assignment (TF versus non-TF) and baseline cannabis use (yes/no) on attendance rates and within-treatment changes in PTSD, alcohol, and non-cannabis drug use severity. Results revealed significant improvements across outcomes among participants in all conditions, with larger PTSD symptom reductions but lower attendance among individuals receiving TF versus non-TF treatment in both cannabis groups. Participants achieved similar reductions in alcohol and drug use across all conditions. TF outperformed non-TF treatments regardless of recent cannabis use, underscoring the importance of reducing barriers to accessing TF treatments for individuals reporting cannabis use.
🧠 While this meta-analysis addresses an important clinical gap by examining trauma-focused treatment outcomes in patients with concurrent PTSD, cannabis use, and other substance use disorders, several limitations warrant careful interpretation. The analysis draws from only four RCTs within a larger Project Harmony dataset, which constrains generalizability, and the abstract does not specify effect sizes, heterogeneity measures, or whether cannabis use was a primary predictor or a stratification variable. Confounders such as cannabis dosing, frequency, cannabinoid profile (THC versus CBD ratios), timing relative to treatment, and concurrent polysubstance use patterns are not detailed but likely influence both symptom trajectories and treatment response. In practice, this work suggests that cannabis use alone should not automatically exclude patients from evidence-based trauma-focused therapies, though clinicians should maintain vigilant monitoring for how active cannabis use might interact with therapeutic processing, particularly during the critical early phases of trauma exposure work.
| |